Related Experiment Video

Updated: Aug 1, 2026

Studying Proteolysis of Cyclin B at the Single Cell Level in Whole Cell Populations
10:54

Studying Proteolysis of Cyclin B at the Single Cell Level in Whole Cell Populations

Published on: September 17, 2012

Highly potent p21(WAF1)-derived peptide inhibitors of CDK-mediated pRb phosphorylation: delineation and structural

D I Zheleva1, C McInnes, A-L Gavine

  • 1Cyclacel Ltd, James Lindsay Place, Dundee, DD1 5JJ, UK.

The Journal of Peptide Research : Official Journal of the American Peptide Society
|October 18, 2002
PubMed

Insights

Researchers identified a small peptide that mimics the tumor suppressor p21, inhibiting cell cycle kinases and offering a potential therapeutic strategy for cancer. This peptide targets cyclin-binding sites, crucial for cell cycle regulation.

Area of Science:

  • Molecular Biology
  • Biochemistry
  • Structural Biology

Background:

  • The tumor suppressor protein p21(WAF1) is crucial for regulating eukaryotic cell-cycle progression by inhibiting cyclin-dependent kinase (CDK) complexes.
  • p21 interacts with CDK/cyclin complexes via a binding groove on the cyclin subunit, which is also involved in recruiting CDK substrates like retinoblastoma protein (pRb) and E2F.
  • Blocking this cyclin-binding groove offers a potential therapeutic strategy to restore p21-like tumor suppression by preventing substrate phosphorylation.

Purpose of the Study:

  • To identify and optimize a minimal bioactive peptide sequence derived from p21's C-terminal cyclin-binding domain.
  • To investigate the structure-activity relationships of this peptide for CDK protein kinase inhibition, specifically targeting pRb phosphorylation.
  • To develop a foundation for peptidomimetic inhibitors of CDKs.

Main Methods:

  • Identification of the minimal bioactive peptide sequence (152)HAKRRLIF(159) from p21.
  • Structure-activity relationship studies involving peptide modifications, including Ser(153) to Ala substitution.
  • Comparison of peptide potency and selectivity against known cyclin-interacting peptides.
  • Construction of a molecular model of the cyclin groove-peptide complex.

Main Results:

  • The optimized peptide (152)HAKRRLIF(159) effectively inhibited CDK protein kinase activity with pRb as the substrate, while leaving histone H1 phosphorylation unaffected.
  • Key residues Arg(155), Leu(157), and Phe(159) were identified as crucial determinants of the cyclin-binding motif.
  • A Ser(153) to Ala mutation significantly enhanced peptide potency and resulted in binding affinity comparable to full-length p21 for CDK2/cyclin A.
  • Molecular modeling supported the observed structure-activity relationships and provided insights into cyclin groove recognition.

Conclusions:

  • The identified minimal peptide sequence represents an optimized inhibitor of CDK/cyclin complexes.
  • The study elucidates the molecular interactions governing cyclin groove recognition, paving the way for rational drug design.
  • These findings lay the groundwork for developing novel peptidomimetic inhibitors targeting CDKs for therapeutic applications in cancer.

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

Related Concept Videos

Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...